New High-Dose flu vaccine trial aims to better protect seniors

NCT ID NCT07302256

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new influenza vaccine in 120 adults aged 60 and older. Participants receive either a high-dose vaccine, a standard-dose vaccine, or a placebo. The study focuses on safety and how well the vaccine triggers an immune response, with the goal of developing a more effective flu shot for older adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Influenza virus split vaccine (high-dose and standard-dose)
What this could lead to
If successful, this could lead to a more effective flu vaccine for older adults, who are at higher risk of severe flu.
What could go wrong
This is a very early Phase 1 trial with only 120 people, so it is primarily checking safety and immune response, not yet proving the vaccine prevents flu. The higher dose may cause more side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Danjiangkou Disease Prevention and Control Center

    RECRUITING

    Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.